FIELD: medicine.
SUBSTANCE: there is claimed isolated human antibody or its fragment, which binds to human EGFR. Antibody contains corresponding CDR areas of light and heavy chain. Its conjugate with anti-neoplastic means or marker is described. Also described are: coding nucleic acid, expression vector, recombinant cell-host for obtaining antibodies and method of inhibiting growth of tumor, expressing EGFR on the basis of antibody.
EFFECT: application of invention provides antibodies with affinity comparable or higher, than in IMC-C225, which neutralises EGFR activation, what can be applied in medicine for treatment of tumours.
36 cl, 14 dwg, 6 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECEPTOR ANTAGONISTS FOR TREATING METASTATIC CANCER | 2009 |
|
RU2455026C2 |
| PDGFRα ANTIBODIES FOR TREATING SECONDARY BONE TUMOUR | 2006 |
|
RU2502523C2 |
| ANTIBODIES SPECIFICALLY BOUND TO EPIDERMAL GROWTH FACTOR RECEPTORS | 2009 |
|
RU2518239C2 |
| TREATMENTS OF CANCER EXPRESSING MUTANT EGF RECEPTORS | 2007 |
|
RU2429014C2 |
| EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY | 2013 |
|
RU2652880C2 |
| COMBINED C-MET AND EGFR ANTAGONISTS THERAPY | 2009 |
|
RU2601892C2 |
| DLL4 ANTIBODIES AND METHODS OF APPLICATION THEREOF | 2007 |
|
RU2415869C2 |
| COMPOSITIONS OF RECOMBINANT ANTIBODIES FROM EPIDERMAL GROWTH FACTOR RECEPTOR | 2009 |
|
RU2540146C2 |
| COMPOSITION CONTAINING ANTIBODY BINDING TO DOMAIN II OF HER2, AND ITS ACIDIC VERSIONS | 2009 |
|
RU2543664C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO COMPONENTS OF THE SIGNAL PATH PD-1, AND TAXANES | 2014 |
|
RU2719487C2 |
